Real-world data show most first-line mTNBC patients are immunotherapy-ineligible, use chemotherapy, and face poorer survival, underscoring major unmet treatment needs.
Aliza Matusevich
Advertisement
Articles by Aliza Matusevich
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC
2
Melanoma Trials You May Have Missed at ASCO 2026
3
75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings
4
VT-EBV-N Yields Durable Disease-Free Survival in Pretreated ENKTL
5